Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Fibrosis Due to NAFLD in Obesity and T2DM
NCT06005012Phase 2Active, not recruiting
- Sponsor
- University of California, San Diego
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide in non-alcoholic fatty liver disease (NAFLD), Liver Fibrosis (LF), sponsored by University of California, San Diego. Started Jul 2023; status: active, not recruiting.
02
Drugs
03
Conditions
non-alcoholic fatty liver disease (NAFLD)Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT06005012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06005012.